(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...
Intuitive Surgical (NASDAQ:ISRG – Free Report) had its target price boosted by JPMorgan Chase & Co. from $575.00 to $675.00 ...
TNYA Stock Performance and Moving Averages. In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -12.95% over the last five trades ...
Walgreens Boots Alliance Inc (WBA) stock saw a modest uptick, ending the day at $11.87 which represents a slight increase of $0.13 or 1.11% from the prior close of $11.74. The stock opened at $11.65 ...
Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
Stock analysts at Leerink Partnrs lifted their Q4 2025 earnings per share (EPS) estimates for shares of Illumina in a ...
For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor. IDRX-42 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback